Atlas market file · Equity · United States
TScan Therapeutics, Inc.TCRX
- Last close
- 0.7632
- Change
- -2.15%
- 96-bar range
- 0.716 – 1.47
- As of
- 6 Aug 2026
TScan Therapeutics, Inc. is a biological products, (no diagnostic substances) issuer listed as TCRX on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
TCRX
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-86.54% over the window).
Source rail: Yahoo Finance chart API (TCRX). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for TCRX. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
TCRX public profile
Biological products, (no diagnostic substances) issuer. TScan Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
TScan Therapeutics, Inc. trades as TCRX on NASDAQ. TScan Therapeutics, Inc. (TCRX) has a latest verified close of 0.7632, down 2.15%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files TCRX under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for TScan Therapeutics, Inc. today
TScan Therapeutics, Inc. (TCRX) is a clinical-stage biotechnology company focused on developing T cell receptor (TCR) engineered T cell therapies for patients with cancer. The company’s latest SEC filings reveal a stark contrast between its ambitious clinical goals and its financial realities. In the quarter ending March 31, 2026, TScan reported a net loss of $28.7 million, a significant increase from its meagre revenue of $982,000 (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1783328/000119312526207572/tcrx-20260331.htm).
The company’s flagship product, TSC-101, is currently in a Phase 1 clinical study (the ALLOHA™ trial, NCT05473910), with the company expressing optimism about the therapeutic effects and potential advantages of its TCR-T therapy product candidates. Despite the clinical progress, the financials paint a grim picture. Operating income (or rather, loss) for the quarter stood at $29.1 million, while cash and cash equivalents were listed at $128.1 million (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1783328/000119312526207572/tcrx-20260331.htm).
TScan’s balance sheet shows assets totaling $202.0 million and liabilities of $105.1 million, leaving stockholders’ equity at $96.9 million. The company’s cash flow from operating activities was a negative $24.3 million, indicating a significant burn rate. Research and development expenses for the quarter were $21.9 million, highlighting the company’s heavy investment in its clinical trials (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1783328/000119312526207572/tcrx-20260331.htm).
For those looking to track TScan’s performance, the company’s SEC filings provide a comprehensive view of its financial health. The latest 10-Q and 8-K filings offer detailed insights into the company’s operations, financials, and insider transactions. While the clinical progress of TSC-101 is a positive signal, the financials suggest a company in need of a significant cash infusion to sustain its operations (source: SEC EDGAR, https://www.sec.gov/edgar/browse/?CIK=1783328).
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
TCRX technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on TCRX
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep TCRX research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
TCRX FAQ
What is TScan Therapeutics, Inc. (TCRX)?TScan Therapeutics, Inc. (TCRX) has a latest verified close of 0.7632, down 2.15%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
TScan Therapeutics, Inc. (TCRX) has a latest verified close of 0.7632, down 2.15%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for TCRX?TScan Therapeutics, Inc. (TCRX) has a latest verified close of 0.7632, down 2.15%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
TScan Therapeutics, Inc. (TCRX) has a latest verified close of 0.7632, down 2.15%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files TCRX under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the TCRX page updated?The TCRX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The TCRX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for TCRX?The TCRX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TCRX. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The TCRX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TCRX. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on TCRX?Yes. The workstation can open TCRX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open TCRX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this TCRX page investment advice?No. The TCRX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The TCRX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →